Streptococcus gallolyticus subsp. pasteurianus Peritonitis in a Patient on Continuous Ambulatory Peritoneal Dialysis
Sir, We report the first case of Streptococcus gallolyticus subsp. pasteurianus peritonitis in a patient on continuous ambulatory peritoneal dialysis (CAPD). A 63-year-old male of Indian origin, on CAPD since April 2013, presented to us with CAPD peritonitis. He was admitted and initiated on intraperitoneal (IP) cloxacillin and ceftazidime as per International Society of Peritoneal Dialysis guidelines. His laboratory investigations were as follows: C-reactive protein 47 mg/L, total white cell count 4.3 × 10 9 /L, peritoneal dialysate (PD) cell count was 200 cells/mm 3 with predominant polymorphs. Dialysate fluid cleared up on day 2 of treatment with subsequent cell count of 25 cells/mm 3 , and corresponding negative cell counts repeated twice. Preliminary reports revealed Gram-positive cocci in the dialysate fluid; therefore, IP ceftazidime was discontinued and IP cloxacillin maintained. However, on day 4 of treatment, PD culture grew S. gallolyticus subsp. pasteurianus, which was resistant to clindamycin, erythromycin, trimethoprim/ sulfamethoxazole, and tetracycline but sensitive to cephalexin and penicillin G. IP cloxacillin was then changed to IP penicillin G 50,000 U per 2 L dialysate bag. He remained asymptomatic and was discharged, to complete 2 weeks of IP penicillin G on an outpatient basis.
Streptococcus has over 50 species in its genus. A serotype classification called Lancefield grouping was used to further classify beta-hemolytic streptococci based on specific carbohydrates present on the bacterial cell wall. S. gallolyticus subsp. pasteurianus is a newly classified group D Streptococcus species previously known as Streptococcus bovis type II/2. S. bovis has 2 biotypes: I and II. This new classification is due to their unique ability to be able to decarboxylate gallic acid. [1] Its unique genetic diversity has resulted in many subspecies that have been associated with an array of clinical implications. [2] They frequently inhabit the gastrointestinal tract of human and animals such as horses, cattle, pigs, and sheep. Besides its association with endocarditis and colorectal carcinoma, S. gallolyticus subsp. pasteurianus has been linked as a causative agent for meningitis and septicemia in patients with colonic carcinoma, cirrhosis, and chronic liver disease. [3, 4] Immunocompromised patients have been known to succumb fatally to septicemia caused by S. gallolyticus subsp. pasteurianus. [5] Our timely initiation of IP ceftazidime and cloxacillin and prompt revision of antibiotics therapy according to antibiogram on day 4 with IP penicillin G led to the successful treatment of peritonitis. Our experience and literature review suggests that S. gallolyticus subsp. pasteurianus infection must not be taken lightly. Awareness regarding the threat posed by this organism is important to ensure the prompt initiation of antimicrobial therapy.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
M. Shanmuganathan, B. L. Goh, C. T. S. Lim 1
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Access this article online

Quick Response Code:
Website:
www.indianjnephrol.org
DOI:
10.4103/ijn.IJN_245_16
Efficacy of Thalidomide for Recurrent Gastrointestinal Bleeding due to angiodysplasias in a Hemodialysis Patient
Sir, A 74-year-old female, on maintenance hemodialysis, presented to us with malena. An upper gastrointestinal (GI) endoscopy and a colonoscopy showed diffuse angiodysplasias involving the entire GI tract (GIT). The small intestine was revisualized with double-balloon enteroscopy. She required several session of argon coagulation and blood transfusion. In spite of the endoscopic and medical treatment, the GIT blood persisted.
We started thalidomide 100 mg/day after informed consent. By 4 months of therapy, the GI bleeding was controlled and the patient had been stable over the last 12 months during our follow-up.
GIT bleeding due to angiodysplastic lesions of the digestive tract is commonly seen among patients on hemodialysis and is responsible for significant morbidity and mortality. [1] Vascular endothelial growth factor (VEGF) is an angiogenic peptide that is secreted in response to hypoxia, stimulates proliferation of vascular endothelial cells, and increases vessel permeability. [2] GIT angiodysplasias are characterized by elevated serum levels of VEGF. [3] Thalidomide is shown to suppress VEGF and leads to a disruption in the pathogenesis behind these pathological vessels. A few studies [4, 5] have shown that thalidomide is an effective and relatively safe therapy for preventing recurrent bleeding. The dose adjustment or reduction is not necessary in patients with chronic kidney disease or in hemodialyzed patients. [5] Thalidomide does not have to be given for an indefinite period, low-dose therapy (100 mg) may be given for 4 months, and bleeding did not recur for many months after cessation of thalidomide. [3] The main side effects attributable to thalidomide are fatigue, constipation, and peripheral neuropathy, all problems that can exist in many dialyzed patients. [5] Fatigue can be partially ameliorated by given the drug at night, and in constipation, laxatives should be added whenever needed. Peripheral neuropathy should be looked for at all phases of therapy and especially after high cumulative doses of thalidomide have been given.
This case illustrates the possible use of thalidomide as a viable therapeutic option in hemodialyzed patients to control GIT bleeding from angiodysplasias.
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